Prafull Ghatage
University of Calgary(CA)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers, Intraperitoneal and Appendiceal Malignancies
Most-Cited Works
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial(2018)604 cited
- → Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial(2019)438 cited
- → Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer(2010)404 cited
- → Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer(2017)391 cited
- → Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group(2011)335 cited
- → Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study(2022)305 cited
- → Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial(2023)282 cited
- → Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer(2011)226 cited
- → Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)(2021)195 cited